ACS
Conditions
Interventions
test group:Fondaparinux anticoagulation therapy
Control group:Low molecular weight heparin anticoagulation therapy
Sponsors
The Second Hospital of Shandong University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged > 18 years old; 2. Diagnosed as a patient with acute coronary syndrome; 3. Patients who have not undergone revascularization and receive conservative treatment; 4. The subject or legal representative has been informed of the nature of the study, understands the provisions of the protocol, can ensure compliance, and signs an informed consent form.
Exclusion criteria
Exclusion criteria: 1. There are contraindications to relevant study drugs: including patients with contraindications to the use of aspirin, ticagrelor, clopidogrel, low molecular weight heparin and fondaparinux; 2. Existence of blood system disease, active bleeding or coagulation dysfunction; 3. Severe liver and kidney dysfunction [Transaminase is greater than 3 times the upper limit of normal, and the creatinine clearance rate is less than 30 ml/(min·1.73m2)]; 4. Other anticoagulant drugs are being taken orally, such as warfarin, etc.; 5. Has participated in the research of other drugs/devices or during the follow-up period of the research of another drug/device; 6. The patient may not comply with the research protocol (including the follow-up period), such as mental disorders, alcohol or drug abuse, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All-cause death within 30 days ;Myocardial infarction again ;Nonfatal stroke;Heavy bleeding; | — |
Secondary
| Measure | Time frame |
|---|---|
| All-cause death and hemorrhage during hospitalization;30 days, 6 months net clinical adverse events;30 days, 6 months of major cardiovascular and cerebrovascular adverse events ; | — |
Countries
China
Contacts
Public ContactWang Xin
The Second Hospital of Shandong University
Outcome results
None listed